
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is for women with womb cancer that has come back or spread to other parts of the body (advanced cancer). Womb cancer is also called uterine or endometrial cancer.
It is for women who have had treatment with chemotherapy that included a platinum drug in the last year.
Treatment for advanced womb cancer can reduce symptoms and help you feel better.
A combination of chemotherapy drugs such as paclitaxel and carboplatin (PC) is a common treatment. But after some time, the cancer may start to grow again. You usually have more treatment with paclitaxel if this happens.
Doctors are looking for ways to help women in this situation. In this trial, they are looking at cediranib and olaparib.
Cediranib is a cancer drug that stops cancer cells from growing new blood vessels.
Olaparib is a PARP inhibitor. It blocks a protein called PARP, which helps damaged cells to repair themselves. Olaparib is already a possible treatment for women with ovarian cancer.
Everyone taking part in this trial has 1 of the following:
The main aim of this trial is to find out whether cediranib and paclitaxel or olaparib helps women with advanced womb cancer.
The following bullet points list the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this trial if all of the following apply:
Who can’t take part
You cannot join this trial if any of these apply.
Cancer related
You:
Medical conditions
You:
Other
You:
This is a phase 2 trial. Researchers hope that around 129 women from the UK will agree to take part.
It is a randomised trial. The women taking part are put into 1 of the following treatment groups by a computer:
Neither you nor your doctor can choose which group you are in.
Paclitaxel
You have paclitaxel as a drip into a vein (intravenously). You have it every week, for 3 weeks. After this you have a break of a week. And then have another 3 weeks of paclitaxel. This continues for as long as it is helping you and the side effects aren’t too bad.
It takes about an hour to have paclitaxel.
Paclitaxel and cediranib
You have paclitaxel in the same way as group 1. And you have cediranib as tablets that you swallow whole, every day.
You continue to have paclitaxel and cediranib for as long as the cancer doesn’t get worse and the side effects aren’t too bad. It can be for up to 6 months.
After 6 months, you may be able to continue to take cediranib alone.
Cediranib and olaparib
You have cediranib and olaparib as tablets that you swallow whole. You take:
This continues for as long as the cancer doesn’t get worse and the side effects aren’t too bad.
Blood tests
You have extra blood tests as part of this trial. Doctors want to find out more about how cediranib and olaparib work. You have the extra blood tests before the start of treatment and at set times during the trial.
You do not need to agree to have the extra blood tests if you don’t want to. You can still take part in this trial.
Tissue sample
Doctors will ask some women who join group 3 to give a tissue sample (biopsy) before the start of treatment. Researchers want to look at the DNA to see why some women are more likely to get womb cancer than others.
Only certain hospitals are helping with this part of the research. Your doctor can tell you more about this.
You do not have to agree to have a biopsy if you don’t want to. You can still take part in this trial.
You see a doctor and have some tests before taking part. The tests might include:
During treatment, you see the trial team 3 times a month if you join group 1 or group 2. You see them every 2 weeks if you join group 3. You have blood tests and a physical examination each time you see them.
You have a CT scan every 6 weeks, for 3 months. You then have a CT scan every 12 weeks.
The trial team will give you a diary to complete at home. They will ask you to keep a record of when you take your tablets. You bring the diary with you to every trial visit.
When you finish treatment, you see the trial team after a month. You then continue to see your doctor as part of your normal follow up.
The trial team monitor you during treatment and afterwards. You have a phone number to call them if you are worried about anything. The team will tell you about all the possible side effects before you start the trial.
The most common side effects of paclitaxel are:
The most common side effects of cediranib are:
The most common side effects of olaparib are:
We have more information about the possible side effects of paclitaxel and olaparib.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Gordon Jayson
University of Manchester
Cardiff University
AstraZeneca
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.